Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Clin Kidney J
2022 Feb 26;158:1475-1482. doi: 10.1093/ckj/sfac062.
Show Gene links
Show Anatomy links
Anaplastic lymphoma kinase inhibitors and their effect on the kidney.
Bonilla M
,
Jhaveri KD
,
Izzedine H
.
???displayArticle.abstract???
Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non-small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice.
Adhikari,
Hypophosphatemia in cancer patients.
2021, Pubmed
Adhikari,
Hypophosphatemia in cancer patients.
2021,
Pubmed
Amatu,
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
2015,
Pubmed
Ardini,
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
2016,
Pubmed
Aydemirli,
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
2021,
Pubmed
Betton,
Minimal Change Disease Induced by Lorlatinib.
2018,
Pubmed
Boulos,
Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells.
2021,
Pubmed
Brunac,
The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript.
2020,
Pubmed
Bullock,
Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys.
1976,
Pubmed
Camidge,
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
2012,
Pubmed
Chabner,
Approval after phase I: ceritinib runs the three-minute mile.
2014,
Pubmed
Costa,
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.
2018,
Pubmed
Crinò,
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
2016,
Pubmed
Cui,
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
2011,
Pubmed
Drilon,
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
2017,
Pubmed
Ferlay,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
2015,
Pubmed
Friboulet,
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
2014,
Pubmed
Fukano,
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
2020,
Pubmed
Gadgeel,
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
2014,
Pubmed
Gambacorti-Passerini,
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
2018,
Pubmed
Gastaud,
Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
2013,
Pubmed
He,
Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report.
2021,
Pubmed
Hill,
Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone.
2016,
Pubmed
Hsiao,
Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature.
2021,
Pubmed
Infarinato,
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
2016,
Pubmed
Izzedine,
The renal effects of ALK inhibitors.
2016,
Pubmed
Izzedine,
Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration.
2021,
Pubmed
Jhaveri,
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.
2017,
Pubmed
Kassem,
Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
2019,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
Lorlatinib induced proteinuria: A case report.
2021,
Pubmed
Li,
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC.
2019,
Pubmed
Lin,
Targeting ALK: Precision Medicine Takes on Drug Resistance.
2017,
Pubmed
Lin,
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
2014,
Pubmed
Marsilje,
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.
2013,
Pubmed
McGee,
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy.
2021,
Pubmed
Moharram,
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia.
2019,
Pubmed
Mossé,
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
2013,
Pubmed
Nagai,
Progressive renal insufficiency related to ALK inhibitor, alectinib.
2018,
Pubmed
Ou,
ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report.
2021,
Pubmed
Pacenta,
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
2018,
Pubmed
Pezeshki,
Advances in pharmacotherapy for neuroblastoma.
2021,
Pubmed
Ramachandran,
Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
2018,
Pubmed
Randhawa,
Tacrolimus (FK506)-Associated Renal Pathology.
1997,
Pubmed
Rolfo,
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
2014,
Pubmed
Salgia,
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?
2021,
Pubmed
Schnell,
Complex renal cysts associated with crizotinib treatment.
2015,
Pubmed
Schulte,
ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.
2021,
Pubmed
Schöffski,
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
2018,
Pubmed
Seto,
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
2013,
Pubmed
Shaw,
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
2014,
Pubmed
Shaw,
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
2020,
Pubmed
Shimada,
Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction.
2017,
Pubmed
Singh,
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
2020,
Pubmed
Singhi,
Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
2018,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Takeyasu,
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors.
2021,
Pubmed
Tucker,
Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.
2015,
Pubmed
Umapathy,
Targeting anaplastic lymphoma kinase in neuroblastoma.
2019,
Pubmed
Wu,
Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
2020,
Pubmed
Yasuda,
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
2012,
Pubmed
Zhang,
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
2016,
Pubmed
Zhao,
Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors.
2019,
Pubmed
Zou,
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
2007,
Pubmed
Zou,
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
2015,
Pubmed
